|
gptkbp:instanceOf
|
gptkb:drug
antiretroviral therapy
|
|
gptkbp:approvalYear
|
2021
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
J05AX27
|
|
gptkbp:brand
|
gptkb:Vocabria
gptkb:Apretude
|
|
gptkbp:CASNumber
|
1051375-16-6
|
|
gptkbp:chemicalFormula
|
carbamoyl pyridone derivative
|
|
gptkbp:combines
|
gptkb:rilpivirine
|
|
gptkbp:developedBy
|
gptkb:ViiV_Healthcare
|
|
gptkbp:drugClass
|
protease inhibitor
|
|
gptkbp:eliminationHalfLife
|
40 days (injection)
|
|
gptkbp:firstApprovedCountry
|
gptkb:United_States
|
|
gptkbp:hasMolecularFormula
|
C19H17F2N3O5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cabotegravir
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:mechanismOfAction
|
inhibits HIV integrase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
consult physician
|
|
gptkbp:prescribes
|
adolescents
adults
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
injection site reactions
|
|
gptkbp:usedFor
|
HIV prevention
HIV treatment
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:ViiV_Healthcare
|
|
gptkbp:bfsLayer
|
7
|